☆ 4.5 Article

Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas

CANCER MANAGEMENT AND RESEARCH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Hematology

Genetic and epigenetic insights into cutaneous T-cell lymphoma

Cornelis P. Tensen et al.

Summary: Significant progress has been made in understanding the pathogenesis of CTCLs in recent years, thanks to advancements in CTCL classifications and technical innovations. These studies have revealed extensive heterogeneity between different CTCL subtypes and identified recurrent alterations that are highly characteristic for specific diagnostic subgroups. These findings have potential implications for the development of targeted therapeutic strategies.

BLOOD (2022)

添加到收藏夹

Review Dermatology

Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management

Amy C. M. Musiek et al.

Summary: Mogamulizumab has shown significant improvement in progression-free survival and overall response rate in MF/SS patients compared to vorinostat, but it commonly causes rash. Due to the variability in clinical and histopathological features of rash associated with mogamulizumab, a multidisciplinary approach is necessary for optimal management.

DERMATOLOGY AND THERAPY (2022)

添加到收藏夹

Article Oncology

Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab

Yuhei Kamada et al.

Summary: In this study, it was found that ATL patients who received Mog treatment before or after allo-HSCT had a higher risk of developing severe GVHD and CMV enteritis, leading to death. The use of Mog also suppressed Treg numbers, and measuring Mog concentration and Treg numbers at the time of allo-HSCT may predict the risk of GVHD.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Oncology

Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study

Marie Jouandet et al.

Summary: Mogamulizumab, a monoclonal antibody, has shown efficacy in extending progression-free survival in patients with advanced refractory cutaneous T-cell lymphomas. Our study provides real-life data on the long-term safety and tolerability of mogamulizumab, suggesting it is a significant treatment option for these patients.

CANCERS (2022)

添加到收藏夹

Article Oncology

Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

Pierluigi Porcu et al.

Summary: This study found that mogamulizumab treatment significantly improved symptoms, function, and overall quality of life in patients with cutaneous T-cell lymphoma compared to vorinostat. Patients with Sezary syndrome showed particularly favorable outcomes with mogamulizumab treatment.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

添加到收藏夹

Review Oncology

Mycosis Fungoides and Sezary Syndrome: Updates and Review of Current Therapy

Hiroaki Kamijo et al.

Summary: While most early-stage MF patients are treated with skin-directed therapies, advanced-stage MF/SS patients are usually treated with systemic treatments including biological or targeted therapies. Due to a lack of randomized controlled studies in the literature, it is necessary to investigate the preferable therapy for each MF/SS patient through comparative prospective trials.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial

Amy C.M. Musiek et al.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Dermatology

Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome

Kelsey E. Hirotsu et al.

Summary: The study highlights the heterogeneous clinical presentation of mogamulizumab-associated rash in patients with MF or SS, making it challenging to clinically distinguish from disease relapse or progression. Recognition of common clinical presentations can help prevent unnecessary discontinuation of treatment with mogamulizumab.

JAMA DERMATOLOGY (2021)

添加到收藏夹

Article Hematology

Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity

Joonhee Park et al.

Summary: The study identified 86 putative driver genes in CTCL, including 19 genes not previously implicated in the disease and two mutations never described in any cancer. Functional assays revealed that these mutations enhance T-cell receptor-dependent proliferation, highlighting their importance in lymphomagenesis. Investigations into genetic causes of CTCL heterogeneity found that while there are broad similarities across disease stages, there are significantly more structural variants in leukemic disease, leading to highly recurrent deletions of putative tumor suppressors.

BLOOD (2021)

添加到收藏夹

Article Dermatology

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

R. A. Cowan et al.

Summary: The post hoc analysis showed that mogamulizumab had greater clinical benefit compared to vorinostat in patients with MF and SS classified as having B1 and B2 blood involvement. The results demonstrated longer progression-free survival, higher objective response rates, and significantly longer time to next treatment with mogamulizumab, especially in patients with higher blood tumor burden.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Dermatology

Mogamulizumab-induced vitiligo in patients with Sezary syndrome: three cases

Abdullah S. Algarni et al.

Summary: Three patients with Sezary syndrome treated with mogamulizumab developed vitiligo, suggesting it may be an immune side effect of the treatment and potentially a favorable predictive factor for treatment response.

EUROPEAN JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Article Pathology

Histopathologic Characterization of Mogamulizumab-associated Rash

Jennifer Y. Wang et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)

添加到收藏夹

Review Oncology

Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients

Gabor Dobos et al.

CANCERS (2020)

添加到收藏夹

Review Oncology

Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sezary syndrome (SS)

Doaa Shalabi et al.

CHINESE CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

R. Willemze et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Dermatology

Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment

Lorenzo Cerroni

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2018)

添加到收藏夹

Article Oncology

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Review Allergy

Dermatological Complications After Solid Organ Transplantation

Luigi Naldi et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince et al.

LANCET (2017)

添加到收藏夹

Article Hematology

Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma

Madeleine Duvic et al.

BLOOD (2015)

添加到收藏夹

Article Oncology

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Julia J. Scarisbrick et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome

Xiao Ni et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Multicenter Phase II Study of Mogamulizumab ( KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Michinori Ogura et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Review Oncology

Skin toxicities associated with epidermal growth factor receptor inhibitors

Tianhong Li et al.

TARGETED ONCOLOGY (2009)

添加到收藏夹

Review Medicine, General & Internal

Mycosis fungoides and Sezary syndrome

Sam T. Hwang et al.

LANCET (2008)

添加到收藏夹

Review Hematology

Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Elise Olsen et al.

BLOOD (2007)

添加到收藏夹

Article Oncology

Significant impact of cutaneous T-cell lymphoma on patients' quality of life - Results of a 2005 National Cutaneous Lymphoma Foundation Survey

Marie-France Demierre et al.

CANCER (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.